Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $4.0 million.

  • Entrada Therapeutics' Other Non-Current Assets changed 0.0% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.0 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Other Non-Current Assets is $4.0 million, which was down 0.0% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Other Non-Current Assets peaked at $13.8 million during Q1 2023, and registered a low of $4.0 million during Q1 2022.
  • Its 4-year average for Other Non-Current Assets is $4.7 million, with a median of $4.0 million in 2022.
  • In the last 5 years, Entrada Therapeutics' Other Non-Current Assets surged by 25045.57% in 2023 and then plummeted by 7146.57% in 2024.
  • Entrada Therapeutics' Other Non-Current Assets (Quarter) stood at $5.2 million in 2022, then decreased by 24.18% to $4.0 million in 2023, then changed by 0.0% to $4.0 million in 2024, then changed by 0.0% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.0 million for Q2 2025, and $4.0 million during Q1 2025.